Loading...
Market
Will J&J's multiple myeloma drug combinations be featured in a major medical journal by December 31, 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Publications in major medical journals like The New England Journal of Medicine, The Lancet, or JAMA
Story
Johnson & Johnson's ($JNJ) New Drug Combinations Show Promise in Multiple Myeloma Treatment
Sep 27, 2024, 12:05 PM
Johnson & Johnson's novel combinations of TALVEY® (talquetamab-tgvs) with TECVAYLI® (teclistamab-cqyv) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) show promising results in treating patients with relapsed or refractory multiple myeloma. The combinations suggest high response rates and durable responses, including in triple-class refractory patients and those with extramedullary disease. These findings indicate potential advancements in treatment options for this challenging condition. The results are significant for Johnson & Johnson ($JNJ) and its partners, including $GMAB.DC and $GMAB.
View original story
Similar markets
Nature • 25%
The Lancet • 25%
JAMA • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
The New England Journal of Medicine • 25%
The Lancet • 25%
JAMA • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%